Research

PhD defense by Weronika Szejniuk

The Department of Clinical Medicine, Aalborg University and Aalborg University Hospital are pleased to invite to PhD defense by MD, Weronika Maria Szejniuk, who will defend the thesis entitled: Non-small cell lung cancer: Prediction of outcome and side effects of platinum-based chemotherapy and high-dose radiation therapy

Time

21.05.2021 kl. 13.00 - 16.00

Description

The PhD defense will take place

On the 21st of May, 2021 at 1 PM

The defense will be held online via Zoom.
Registration by e-mail to inst.klinisk.phd@dcm.aau.dk

 

Main supervisor

Prof. Oluf Dimitri Røe, MD, PhD
Dept. of Oncology, Aalborg University Hospital & Dept. of Clinical Medicine, Aalborg University, Denmark & Cancer Clinic, Levanger Hospital & Dept. of Clinical and Molecular Medicine, NTNU, Trondheim, Norway
 

Assistant supervisors

Prof. Ursula Gerda Falkmer, MD, PhD
Dept. of Oncology & Clinical Cancer Research Center, Aalborg University Hospital & Dept. of Clinical Medicine, Aalborg University, Denmark

Prof. Martin Bøgsted, MSc, PhD
Dept. of Clinical Medicine, Aalborg University & Dept. of Haematology, Aalborg University Hospital

Asst. Prof. Martin Skovmos Nielsen, MSc, PhD
Dept. of Medical Physics, Aalborg University Hospital Dept. of Clinical Medicine, Aalborg University


Assessment Committee

Prof. Alkwin Wanders, MD, PhD (chairman)
Dept. of Clinical Medicine, Aalborg University, Denmark

Prof. Åslaug Helland, MD, PhD
Dept. of Oncology, Oslo University Hospital & Institute of Cancer Research, University of Oslo, Norway

Assoc. Prof. Simon Ekman, MD, PhD
Dept. of Oncology-Pathology, Karolinska Institute, Sweden

 

About the PhD thesis

Lung cancer is the main cause of cancer-related mortality worldwide. More than 80% of all lung cancer cases include non-small cell lung cancer (NSCLC). Early stage NSCLC is a potentially curable disease by means of surgical treatment followed by adjuvant platinum-based chemotherapy in certain defined cases. Locally advanced stage of NSCLC is treated with chemotherapy combined with radiation therapy (RT). In both therapeutic modalities, toxicity and the risk of adverse effects are treatment-limiting factors. There is a need for clinical models and biomarkers that predict treatment outcomes and provide assistance in decision-making when using these therapeutic modalities.

The first study summarises the potentially clinically useful epigenetic biomarkers of sensitivity to platinum-based chemotherapy in NSCLC. The second study investigated the influence of relative dose-intensity of cisplatin in adjuvant platinum-based chemotherapy on the survival of patients with early stage NSCLC. The results showed that low relative dose-intensity of cisplatin was associated with significantly shorter survival. Furthermore, the study revealed that treatment delay did not affect survival. The third study presents the results of a prospective observational study of fractional exhaled nitric oxide (FeNO) as predictive marker for radiation pneumonitis (RP). The results showed that higher values of the mean FeNO could identify a group of patients at risk of symptomatic RP after RT for NSCLC. Finally, the fourth study analysed the potential of a novel radiological grading scale of radiation-induced lung injury (RGS) for prediction of symptomatic RP. The results showed that patients with higher grades of lung injury had greater risk of RP development and were associated with a higher incidence of RP. Moreover, higher RGS grades were associated with a higher incidence of RP and earlier onset of RP symptoms after RT compared to patients with lower grades of RGS.

Host

Department of Clinical Medicine, Aalborg University

Address

Online via Zoom

Registration Deadline

20.05.2021 kl. 12.00

Register at

inst.klinisk.phd@dcm.aau.dk

Events

See the list